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Abstract Genomic instability is a hallmark of human cancer, and results in widespread somatic
copy number alterations. We used a genome-scale shRNA viability screen in human cancer cell lines
to systematically identify genes that are essential in the context of particular copy-number
alterations (copy-number associated gene dependencies). The most enriched class of copy-number
associated gene dependencies was CYCLOPS (Copy-number alterations Yielding Cancer Liabilities
Owing to Partial losS) genes, and spliceosome components were the most prevalent. One of these,
the pre-mRNA splicing factor SF3B1, is also frequently mutated in cancer. We validated SF3B1 as a
CYCLOPS gene and found that human cancer cells harboring partial SF3B1 copy-loss lack a
reservoir of SF3b complex that protects cells with normal SF3B1 copy number from cell death upon
partial SF3B1 suppression. These data provide a catalog of copy-number associated gene
dependencies and identify partial copy-loss of wild-type SF3B1 as a novel, non-driver cancer gene
dependency.
DOI: 10.7554/eLife.23268.001
Introduction
Despite recent advances in cancer therapeutics, there remains a dearth of effective treatments.
Therefore, expanding the number of candidate therapeutic targets in cancer is crucial. Cancer ‘driver
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genes’, which undergo positive selection due to their effects on oncogenes or tumor suppressor
genes, represent cancer vulnerabilities that are broadly considered as potential therapeutic targets
(Cheung et al., 2011; Eifert and Powers, 2012; Wang et al., 2015). However, alterations of non-
driver genes, which do not contribute to oncogenesis but are nevertheless observed, represent an
emerging class of candidate therapeutic target that have yet to be fully explored.
During the course of tumorigenesis, most cancers undergo somatic copy number alterations
(SCNAs) affecting large fractions of the genome (See Appendix Note) (Beroukhim et al., 2010). Yet
most genes affected by SCNAs likely do not contribute to oncogenesis and are therefore over-
whelmingly genetically altered non-driver genes. Recently, our laboratory and others have described
potential new therapeutic targets that occur as a result of SCNAs affecting non-driver genes. For
example, partial copy-loss of the proteasome subunit PSMC2, or RNA polymerase subunit POLR2A
sensitized cancer cells to further suppression of those genes (Liu et al., 2015; Nijhawan et al.,
2012). This ‘CYCLOPS’ (Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS)
phenotype suggests that many additional cancer vulnerabilities exist as a result of SCNAs that affect
non-driver genes, although some CYCLOPS genes may function as driver genes when affected by
other genetic alterations besides partial copy-loss. The frequency of these CYCLOPS gene depen-
dencies and their general features are largely unknown.
These CYCLOPS genes tend also to be cell essential genes. While essential genes would be
expected to be poor therapeutic targets because of their requirement for survival in all tissues, ther-
apeutic windows can still exist (Muller et al., 2015). Identifying which essential genes may be consid-
ered CYCLOPS genes, and the mechanisms underlying how normal cells tolerate partial loss of
function, is necessary for developing approaches to target those therapeutic windows.
The spliceosome is one such essential protein complex that can be therapeutically targeted in
cancer. Previous work suggested spliceosome components were enriched as candidate CYCLOPS
genes (Nijhawan et al., 2012). However, spliceosome CYCLOPS dependencies have yet to be vali-
dated and the molecular mechanisms for how spliceosome CYCLOPS dependencies arise remain
unclear. Compounds have been discovered that inhibit pre-mRNA splicing, with reports of broad
anti-neoplastic effects (Webb et al., 2013). Furthermore, cancers can harbor recurrent mutations in
splicing factors (Dvinge et al., 2016), including gain-of-function mutations in SF3B1 (Ellis et al.,
2012; Harbour et al., 2013; Imielinski et al., 2012; Papaemmanuil et al., 2011; Wang et al.,
2011; Yoshida et al., 2011) that can sensitize cells to spliceosome modulatory drugs (Obeng et al.,
2016). In addition to SF3B1 mutations, other genomic alterations in SF3B1, including copy number
alterations, may also unveil novel cancer vulnerabilities. The extent to which SF3B1 and other splicing
factors can be leveraged as therapeutic targets in cancer is not fully understood.
We therefore sought to systematically evaluate the prevalence of CYCLOPS dependencies rela-
tive to other SCNA-associated gene dependencies in cancer. Here, we report that CYCLOPS depen-
dencies are the most enriched class of copy-number associated gene dependency, even more
frequent than amplification of oncogene-addicted driver gene. We find that CYCLOPS genes tend
to be a subset of essential genes for which there is little feedback regulation in their expression
when altered by SCNAs. We also find that more CYCLOPS gene dependencies are associated with
spliceosome components than with any other gene family.
We find that wild-type SF3B1 is a non-driver CYCLOPS gene dependency and describe the mech-
anism behind this dependency. Furthermore, the molecular mechanism of the SF3B1 CYCLOPS
dependency is distinct from SF3B1 dependencies targeted by current spliceosome inhibitors. We
also identify the deubiquitinase inhibitor (DUBi’s), b-AP15, can reduce SF3B1 protein levels and tar-
get the SF3B1 CYCLOPS dependency. Moreover, DUBi’s may represent a general therapeutic
approach to target CYCLOPS gene vulnerabilities. The identification of SF3B1 as a CYCLOPS gene
highlights a previously unrecognized cancer vulnerability and implicates non-driver alterations of
wild-type SF3B1 as a potential therapeutic target present in 11% of all cancers.
Paolella et al. eLife 2017;6:e23268. DOI: 10.7554/eLife.23268 2 of 35
Research article Cancer Biology Human Biology and Medicine
Results
Most copy-number associated cancer dependencies result from
genomic loss
We interrogated copy-number associated vulnerabilities genome-wide across 179 cell lines by inte-
grating gene dependency data from Project Achilles (Cowley et al., 2014) with copy-number calls
for 23,124 genes (Barretina et al., 2012) (Figure 1A). The gene dependency data represented the
effects on proliferation of 55,416 shRNAs targeting 11,589 unique genes, processed by the ATARiS
method to estimate effects of ‘on-target’ shRNAs (Shao et al., 2013), which yielded 8724 unique
gene-level dependency scores. For every pair of genes in the general analysis, we calculated Pearson
correlations between the copy-number of the first gene and the dependency score of the second;
yielding 201,733,776 parings in total (Figure 1A). We calculated p-values for each correlation and
q-values to correct for multiple hypotheses (see Materials and methods). In many cases, a single
gene dependency profile correlated with copy-number profiles of multiple genes from a single
genomic region. We considered these to represent a single ‘independently significant’ interaction
with the overall copy-number of that region.
In the general analysis, we identified 50 independently significant copy-number:gene-dependency
interactions (q < 0.25; Supplementary file 1A). Approximately two-thirds (33/50) of these interac-
tions involved genes on separate chromosomes (trans interactions). Among the 33 trans interactions,
21 reflected sensitization to suppression of a gene resulting from copy-loss of a different genomic
region; the other 12 resulted from copy-gains. The trans gene dependencies identified were
enriched for members of macromolecular complexes (q = 2.510 4). In three cases, copy-loss of a
gene (PPP2CB, FUBP2, or MAGOH) was associated with increased sensitivity to suppression of its
paralog (PPP2CA, FUBP1, and MAGOHB, respectively). In contrast, all but one interaction (16/17)
between genes on the same chromosome (cis interactions) involved increases in sensitivity to sup-
pression of a gene that had undergone copy-loss (CYCLOPS genes) (Nijhawan et al., 2012). As a
result, 74% of all 50 significant copy-number:gene-dependency interactions were associated with
copy-loss rather than gain (p=1.510 4).
Most cancers exhibit losses of candidate CYCLOPS genes
Although CYCLOPS interactions represent 0.004% (8,724/201,733,776) of all potential interactions in
the general analysis, they constituted one-third of all significant interactions, making them the most
enriched class of copy-number synthetic lethal interactions we identified (Figure 1B). Their preva-
lence is partly the result of frequent genomic loss in cancer genomes. Specifically, across 10,570 can-
cers spanning 31 cancer types profiled by The Cancer Genome Atlas (TCGA), 16% of the genome
undergoes loss in the average cancer (Figure 1—figure supplement 1A), mainly due to losses
encompassing chromosome arms or entire chromosome (Figure 1—figure supplement 1B). Indeed,
loss of a tumor suppressor often involves such arm-level losses (Figure 1—figure supplement 1C).
The fraction of the genome lost per tumor ranged from an average of 1.3% in thyroid cancer to
34.4% in ovarian cancer (Figure 1C).
To enhance the identification of CYCLOPS genes, we performed a genome-wide analysis focused
on just CYCLOPS dependencies (Figure 1D; Materials and methods). The CYCLOPS analysis had
greater power than the general analysis described above because it focused on fewer hypotheses.
From the CYCLOPS analysis, we identified 124 candidate CYCLOPS genes (Supplementary file 1B),
including 87% of the candidate CYCLOPS genes identified in the general analysis
(Supplementary file 1A). Candidate CYCLOPS genes were distributed across all autosomes
(Figure 1E) and were biased towards areas of frequent copy-loss (p<10 15). The bias toward more
frequent copy-loss of candidate CYCLOPS genes may reflect greater statistical power in frequently
deleted regions. We also examined the reproducibility of the CYCLOPS analysis using a separate
shRNA viability screen across 77 cell lines with a separate analytical approach (Marcotte et al.,
2016) and found 49% (49/103) of the CYCLOPS genes analyzed by both datasets validated in the
Marcotte dataset (p<210 4, binomial proportion test).
Partial copy-loss of candidate CYCLOPS genes is frequent in cancer genomes. Among the 10,570
TCGA cancers with copy-number data, 71.6% harbored loss of at least one candidate CYCLOPS
Paolella et al. eLife 2017;6:e23268. DOI: 10.7554/eLife.23268 3 of 35
Research article Cancer Biology Human Biology and Medicine
0 5 10 15 20
Normalized variance in expression 
across normal tissues
All genes
Essential genes
CYCLOPS genes
D
A
C
Copy-numbers Gene dependencies
Copy-number 
of gene X
 r
etf
a
 ytilib
aiV
 
n
oiss
erpp
us
 Y
 
e
n
eg
For all gene pairs
+
s
er
ocs
 
edi
w
e
m
o
n
e
G
)s
e
nil
 ll
ec
 971(
50 significant interactions
sisyl
a
n
a
 l
ar
e
n
e
G
B
-4
-2
0
2
Neutral Hemizygous
loss
Copy-number of gene N
 r
etf
a
 ytlib
aiV
 
n
oiss
erpp
us
 
N
 
e
n
eg
sisyl
a
n
a
 SP
OLCYC
124 significant interactions
8,724 genes
Nu
m
be
r o
f C
YC
LO
PS
 
ge
n
es
 lo
st
 
pe
r 
tu
m
or
0
50
10
0
THCA KIRP COAD BRCA LUAD LUSC OV
Tumor type
-200
-100
0
100
200
CYCLOPSlo
g 
p-
va
lu
e
gain loss
Interaction type:
Depletion
Enrichment
gain loss
trans cis
0
20
40
60
Pe
rc
en
t o
f g
en
om
e l
os
t
ov kic
h
uc
s
lus
c
es
ca
lua
d
sa
rc
ch
ol
blc
a
sk
cm br
ca
hn
sc
re
ad lih
c
m
es
o
ce
sc
st
ad ac
c
pa
ad gb
m
co
ad
pc
pg kir
c
lgg
uc
ec
pr
ad
uv
m
dlb
c
kir
p
lam
l
th
ca
E
0
0.
5
1.
0
1.
5
Genomic Position
De
lta
 A
ta
ris
 S
co
re
Hemizygous deletion frequencyCYCLOPS gene 0.75
0.5
0.25
0
Frequency of partial loss
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1819 2117 22
F G
Figure 1. Analysis of copy-number-associated gene dependencies. (A) Schematic describing the general analysis of copy-number-associated gene
dependencies. (B) Significance of enrichment for positive copy-number:gene dependency associations across trans and cis association classes, relative
to the expected share assuming all possible interactions exhibited equal likelihood of positive association. (C) Percent of genome lost across 31 TCGA
cancer types. Cancer types are indicated by TCGA abbreviations (see https://tcga-data.nci.nih.gov/datareports/codeTablesReport.htm, ‘Disease Study’
Figure 1 continued on next page
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gene (Figure 1F). The average number of candidate CYCLOPS genes lost per tumor ranged from
one in thyroid cancer to 47 in ovarian cancer.
Candidate CYCLOPS genes tend to be uniformly expressed members of
essential complexes
Of the 124 candidate CYCLOPS genes, 20 were members of the spliceosome and 11 were members
of the proteasome, making these the only significantly enriched KEGG pathways among candidate
CYCLOPS genes (Supplementary file 1D). Candidate CYCLOPS genes are also enriched for essen-
tial genes. Genome-wide CRISPR viability data in human cancer cell lines identified 1580 core-essen-
tial genes (Hart et al., 2015), including 58% (72/124) of candidate CYCLOPS genes (p<210 4,
binomial proportion test).
Expression of candidate CYCLOPS genes is markedly uniform across normal tissues. Across RNA-
sequencing data from 2342 samples comprising 42 tissue types (Mele´ et al., 2015), expression of
candidate CYCLOPS genes varied significantly less than that of the average gene (p=1.810 15) and
trended towards greater uniformity than non-CYCLOPS essential genes (p=0.07; Figure 1G).
However, expression of candidate CYCLOPS genes is highly responsive to genomic loss in cancer.
We integrated expression profiles for 16,867 genes with copy-number profiles across 1011 cell lines
in the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012) to determine the influence of
copy-number on gene expression. Upon copy-loss, CYCLOPS gene expression decreased by 28% on
average, relative to an 18% decrease among non-CYCLOPS genes (p<10 4, Figure 1—figure sup-
plement 1D–E). These data suggest that cancers with copy-loss of CYCLOPS genes are likely to
express them at lower levels than normal tissues.
SF3B1 is a CYCLOPS gene
SF3B1 was among the most significant candidate genes in our CYCLOPS analysis
(Supplementary file 1B), although it was not detected in our general analysis (Supplementary file
1A). The SF3B1 protein is one of seven subunits (SF3B1–5, SF3B14 and PHF5A) of the SF3b com-
plex, which is a constituent of the essential U2 snRNP splicing factor (Wahl et al., 2009). Cells with
SF3B1 copy-loss exhibited significantly reduced viability upon partial SF3B1 suppression relative to
cells without SF3B1 copy-loss (mean dependency scores of  1.14 and 0.01 respectively, p<10 5),
which suggests that partial suppression of SF3B1 can be tolerated in certain contexts even though it
is an essential gene.
SF3B1 is partially lost in 11% of the 10,570 cancers from the TCGA PanCan dataset (see Materials
and methods for definitions of copy number states). Across all cancers SF3B1 copy-loss was 5.4
times more common than SF3B1 mutations, which occur in ~2% of all cancers (Supplementary file
1C), and mutations and copy-loss were mutually exclusive (p=0.007). Losses were more frequent in
breast (20%), urothelial bladder (32%) and chromophobe kidney cancers (71%). Genomic deletions
of SF3B1 typically affect most of the chromosome arm (81% of losses) and are never homozygous (0/
10,570 cancers), consistent with characterization of SF3B1 as an essential gene (An and Henion,
2012; Isono et al., 2005). In contrast, 85% of genes are homozygously deleted at least once among
the same 10,570 cancers. Similarly, analysis of copy number alterations from 1042 cancer cell lines in
the CCLE indicated 24% of cell lines harbor partial SF3B1 deletion, including 16/61 (26%) of breast
cancer cell lines, but never homozygous loss (0/1042 cell lines).
Figure 1 continued
table). (D) Schematic describing the approach to identify CYCLOPS genes. (E) Relative strength (delta ATARiS score) of CYCLOPS genes (orange circles;
left axis) and frequency of hemizygous deletion (solid black line; right axis) against genomic position (x-axis). (F) The number of CYCLOPS genes lost
per tumor for various tumor types as in (C). Horizontal black lines represent medians per tumor type. (G) Distribution of variances in gene expression for
different gene classes, normalized to expression level (see Materials and methods), in normal tissues. Whiskers represent min/max values and boxes
represent upper and lower quartile ranges. Width of plots represents relative sample density.
DOI: 10.7554/eLife.23268.002
The following figure supplement is available for figure 1:
Figure supplement 1. Analysis of copy-number-associated gene dependencies.
DOI: 10.7554/eLife.23268.003
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We established the vulnerability of SF3B1loss cells to SF3B1 suppression in both breast and
hematopoietic lineages. We tested the proliferation of six breast lines after partial SF3B1 suppres-
sion, including three lines with SF3B1 copy-loss (SF3B1loss) and three without either loss or gain of
the gene (SF3B1neutral). Upon partial SF3B1 suppression, SF3B1loss cells exhibited significant growth
defects but SF3B1neutral cells or SF3B1gaincells did not (Figure 2A and Figure 2—figure supplement
1A). Growth defects observed in SF3B1loss cells included BT549, a near triploid cell line with two
copies of SF3B1. Partial SF3B1 suppression also decreased the growth of ESS1, an endometrial cell
line harboring an SF3B1K666N mutation (Figure 2A and Figure 2—figure supplement 1A). However,
complete SF3B1 suppression resulted in growth defects even in SF3B1neutral cells (Figure 2—figure
supplement 1B–C), consistent with previous work establishing SF3B1 as an essential gene.
The SF3B1 shRNAs used to unveil the CYCLOPS vulnerability targeted separate regions of the
gene and resulted in partial SF3B1 knockdown across all eleven breast cell lines (Figure 2B). How-
ever, SF3B1loss cells had greater levels of knockdown due to lower SF3B1 expression at baseline,
which was confirmed at the protein level in four of these lines by immunoblot (Figure 2—figure sup-
plement 1D).
We also generated similar results in isogenic SF3B1loss cells derived from the SF3B1neutral cell line
Cal51. We generated SF3B1loss cells using two independent CRISPR-Cas9 mediated methods of
gene editing (see Materials and methods). The first line contained a frameshift mutation inactivating
one SF3B1 allele (SF3B1Loss-Cal51-1). The second line had deletion of one copy of the SF3B1 locus,
generated by co-expressing two sgRNAs: one upstream targeting a heterozygous SNP, and one
downstream of SF3B1 (SF3B1Loss-Cal51-2). In both cases CRISPR-mediated SF3B1 loss resulted in
decreased proliferation upon SF3B1 suppression relative to cells that were generated in parallel but
did not produce inactivating alleles (SF3B1control-Cal51 cells; Figure 2A and Figure 2—figure supple-
ment 1A).
We confirmed the vulnerability of the SF3B1loss cells to SF3B1 partial suppression using a GFP-
competition assay in which we compared the proliferation rate of uninfected cells co-cultured with
cells infected with a vector that co-expressed GFP and an shRNA targeting either LacZ or SF3B1.
The expression of LacZ or SF3B1 shRNAs did not result in significant changes in proliferation of
SF3B1neutral cells in seven cell lines, including the non-transformed mammary cell line, MCF10A
(Figure 2C and Figure 2—figure supplement 1E). However, SF3B1loss cells expressing SF3B1
shRNAs were not compatible with long-term culture (Figure 2C and Figure 2—figure supplement
1E).
The SF3B1 CYCLOPS vulnerability is not recapitulated by suppression of other SF3b complex sub-
units, and copy number alterations of other SF3b complex genes do not confer susceptibility to
SF3B1 suppression. We calculated the significance of associations between Achilles RNAi depen-
dency data of six of the seven SF3b complex subunits (we lacked RNAi data for SF3B2) and copy
numbers of the genes encoding them (Figure 2—figure supplement 1F). We identified associations
between copy numbers of several SF3b subunits and sensitivity to suppressing that same subunit,
consistent with our prior determination that multiple SF3b complex subunits are candidate
CYCLOPS genes (Supplementary file 1B). However, we observed no associations between suscepti-
bility to suppression of any of the SF3b complex genes and copy numbers of different SF3b subu-
nits. Further, we confirmed one comparison where suppression of PHF5A, an SF3b complex gene,
did not alter the growth of SF3B1loss cells (Figure 2—figure supplement 1G–H).
Partial suppression of SF3B1 leads to both cell cycle arrest and apoptosis in SF3B1loss but not
SF3B1neutral lines. We generated cultures containing a tetracycline inducible system expressing hair-
pins targeting Luciferase or SF3B1 (TR-shSF3B1#3 and an additional hairpin, TR-shSF3B1#5, Fig-
ure 2—figure supplement 1A), enabling us to discriminate SF3B1 suppression from infection with
shRNA vectors. Consistent with stable SF3B1 suppression, inducible SF3B1 suppression retards
SF3B1loss cell growth and does not affect SF3B1neutral growth (Figure 2—figure supplement 1B)
and reduces cell viability in SF3B1loss cells but not in SF3B1neutral cells (Figure 2D and E). SF3B1loss
cells had significantly increased proportions of cells in G2/M phase after SF3B1 suppression, which
did not occur in SF3B1neutral cells (Figure 2F). Subsequent to G2/M arrest, SF3B1loss cells further
exhibited a significant induction in apoptosis as determined by increased number of AnnexinV/PI-
positive cells that was not observed in SF3B1neutral cells (Figure 2G).
Expression of exogenous SF3B1 rescued the loss of viability in SF3B1loss cells, confirming the
specificity of our shRNAs. We used a lentiviral construct encoding a codon-optimized SF3B1 ORF,
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Figure 2. Characterization of SF3B1 as a CYCLOPS gene. (A) Growth of breast cancer cell lines expressing shLacZ (black) or shSF3B1 (red and orange),
measured as changes in CellTiterGlo luminescence relative to one day post-infection. (B) Quantitative RT-PCR of SF3B1 expression from the indicated
cell lines expressing shLacZ or shSF3B1 shRNAs normalized to the diploid SF3B1neutral cell line Cal51. (C) Ratio of cells expressing shSF3B1-GFP relative
to uninfected controls, normalized to the ratio of cells expressing shLacZ-GFP relative to uninfected controls. Data represent averages from SF3B1neutral
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which is resistant to shRNA suppression, fused to an IRES GFP sequence (SF3B1WT-IRES-GFP). When
placed in competition, cells infected or not infected with SF3B1WT-IRES-GFP maintained constant
ratios over 10 days (Figure 2H), suggesting that short-term expression of SF3B1 does not alter cellu-
lar fitness in either SF3B1neutral or SF3B1loss cells. Next, we concomitantly suppressed endogenous
SF3B1 in all cells and expressed SF3B1WT-IRES-GFP in ~50% of cells. While SF3B1neutral cells were
not affected by partial SF3B1 suppression, SF3B1loss cells expressing shSF3B1 were not compatible
with long-term culture. However, SF3B1loss cells expressing both shSF3B1 and SF3B1WT-IRES-GFP
persisted (Figure 2I), indicating that re-expression of SF3B1 is sufficient to prevent cell death. Fur-
thermore, SF3B1loss cells expressing both shSF3B1 and SF3B1WT-IRES-GFP had a 20-fold increase in
GFP fluorescence, suggesting that the exogenous SF3B1 construct was more highly expressed in
SF3B1loss cells after suppression of endogenous SF3B1 (Figure 2—figure supplement 1C). Further-
more, stable exogenous SF3B1 expression is sufficient to restore the proliferation of SF3B1losscells
expressing shRNAs targeting SF3B1 (Figure 2J and Figure 2—figure supplement 1D).
SF3B1neutral cells contain excess SF3B1 beyond the requirement for
survival
Analyses of SF3B1 mRNA indicate that SF3B1neutral cells tolerate partial SF3B1 suppression because
they express more SF3B1 than the minimum amount needed for survival. In both TCGA breast ade-
nocarcinoma data (Cancer Genome Atlas Network, 2012) and the Cancer Cell Line Encyclopedia,
SF3B1neutral samples exhibited significantly higher expression of SF3B1 mRNA relative to SF3B1loss
samples (Figure 3A and Figure 3—figure supplement 1A; Mann-Whitney p<10 4, for both data-
sets), suggesting excess mRNA over requirements for survival. We validated that SF3B1neutral breast
cancer cell lines (n = 7) express approximately twice as much SF3B1 mRNA as SF3B1loss cells (n = 5)
by quantitative PCR (Figure 3B; p<10 4). We also found similar SF3B1 expression changes between
the SF3B1control-Cal51 and SF3B1Loss-Cal51 lines (Figure 3—figure supplement 1B).
Reductions in SF3B1 mRNA expression were recapitulated at the protein level. Among breast
cancer lines, we found increased SF3B1 protein expression in SF3B1neutral compared to SF3B1loss
cells (Figure 3C) and SF3B1control-Cal51 vs. SF3B1Loss-Cal51 cells (Figure 3D). We also a found signifi-
cant linear correlation between SF3B1 mRNA and protein expression (Figure 3E, p=0.0018,
R2 = 0.772).
These observations suggest that SF3B1neutral cells tolerate partial SF3B1 suppression because
moderate SF3B1 suppression leaves them with sufficient residual protein for survival. Indeed, we
found detectable SF3B1 levels in SF3B1neutral cells after SF3B1 suppression, but failed to detect pro-
tein in SF3B1loss cells after SF3B1 suppression (Figure 3F and Figure 2—figure supplement 1D).
A systematic analysis of shRNA-induced mRNA suppression across SF3B1neutral and SF3B1loss lines
indicated that SF3B1 mRNA levels can be reduced by ~60% from SF3B1neutral cell basal levels before
proliferation and viability defects are apparent (Figure 3G). We suppressed SF3B1 using shRNAs
with different potency to generate a range of SF3B1 suppression in SF3B1neutral and SF3B1loss cells,
including shRNAs that suppress SF3B1 by >70% in SF3B1neutral cells, and determined the impact on
Figure 2 continued
(n = 7) and SF3B1loss (n = 6) cell lines, using shSF3B1 #4 in Figure 2—figure supplement 2E. (D) Viability of cells expressing TR-shSF3B1#3 and
TRshSF3B1#5, relative to viability three days post doxycycline administration. (E) Viability of cells expressing shLacZ or the average of shSF3B1#3 and
shSF3B1#4, measured asthe fraction of propidium iodide negative cells, relative to the viability of these cells four days post infection. (F) Cell cycle
distribution four days after SF3B1 suppression averaged from TR shSF3B1#3 and #5. (G) Fraction of apoptotic cells five days after SF3B1 suppression
averaged from TR shSF3B1#3 and #5, as determined by AnnexinV/PI flow cytometry. (H) Change in ratio of cells expressing SF3B1-GFP relative to
uninfected cells. (I) Ratio of cells expressing SF3B1-GFP to uninfected cells, in the context of endogenous SF3B1 suppression with TR-shSF3B1 #5. (J)
Growth of LacZ and SF3B1 expressing SF3B1loss cells upon SF3B1 suppression (TR-shSF3B1#5), measured as changes in CellTiter-Glo luminescence. For
all panels, *p<0.05 **p<0.01 ***p<0.001, and error bars represent ± SD from at least three (panels A–G) or two (H–J) replicates.
DOI: 10.7554/eLife.23268.004
The following figure supplements are available for figure 2:
Figure supplement 1. Characterization of SF3B1 as a CYCLOPS gene.
DOI: 10.7554/eLife.23268.005
Figure supplement 2. Further characterization of SF3B1 as a CYCLOPS gene.
DOI: 10.7554/eLife.23268.006
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Figure 3. SF3B1neutral cells contain excess SF3B1 beyond the requirement for survival. (A) SF3B1 expression from 777 TCGA breast adenocarcinomas
segregated by SF3B1 copy number. Whiskers represent min/max values and boxes represent upper and lower quartile ranges. Width of plots
represents relative sample density. (B) Quantitative RT-PCR of SF3B1 expression in breast cancer cell lines. Data points represent individual cell lines,
horizontal lines indicate means. (C) SF3B1 protein levels in breast cancer cell lines by immunoblot. (D) SF3B1 immunoblot from control cells and those
Figure 3 continued on next page
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cellular growth seven days after shRNA expression. Although similar reductions in SF3B1 expression
were obtained in SF3B1neutral and SF3B1loss lines, the elevated basal levels of SF3B1 expression in
SF3B1neutral lines enabled them to retain sufficient SF3B1 for proliferation despite shRNA expression,
except in cases when SF3B1 suppression exceeded the 60% threshold of viability.
SF3B1 copy-loss selectively reduces the abundance of the SF3b
complex
We next asked whether the reduction of SF3B1 protein expression in SF3B1loss cells preferentially
altered specific SF3B1-containing complexes. SF3B1 is a component of the seven-member SF3b
sub-complex of the U2 snRNP. Incorporation of SF3b into the U2 snRNP 12S ‘core’ forms the 15S
U2 snRNP, which combines with SF3a to form the mature 17S U2 snRNP (Figure 4A) (Kra¨mer et al.,
1999; van der Feltz et al., 2012). We therefore interrogated expression levels of native SF3B1-con-
taining complexes from whole-cell extracts by glycerol gradient sedimentation and gel filtration
chromatography. We were able to resolve protein complexes from 29–650 kDa and 650–2,000 kDa
using 10–30% glycerol gradients and Sephacryl S-500 gel filtration chromatography, respectively
(Figure 4—figure supplement 1A–B). This enabled resolution of SF3B1-containing complexes rang-
ing from monomers (155 kDa) to the SF3b sub-complex (450 kDa) to the 15S and 17S U2 snRNPs
(790 and 987 kDa, respectively) (van der Feltz et al., 2012). We compared these elution profiles
between patient-derived and isogenic SF3B1loss and SF3B1neutral cells.
We observed significantly lower levels of SF3b in the SF3B1loss cells. The largest decreases in
SF3B1-containing complexes in glycerol gradients were in fractions 4–8, corresponding to ~29–450
kDa (Figure 4B–F) and fractions 12–14, corresponding to ~450–650 kDa (Figure 4G and Figure 4—
figure supplement 1C). We saw similar decreases in gel filtration chromatography fractions corre-
sponding to complexes <650 kDa (Figure 4—figure supplement 1D). Native western blotting from
the pooled glycerol gradient fractions 4–6 indicated the loss of a single SF3B1-containing complex
of ~450 kDa (Figure 4H). SF3B1 immunoprecipitation from fractions 4–6 resulted in the co-precipita-
tion of SF3b components SF3B3 and SF3B4 in SF3B1neutral cells, but not of U2 snRNP components
SNRPB2 and SF3A3 (Figure 4—figure supplement 1E).
Conversely, it appears that U2 snRNP levels are only modestly decreased in SF3B1loss lines. Levels
of SF3B1 in glycerol gradient fraction 25 (corresponding to >650 kDa) were not significantly
decreased in SF3B1loss relative to SF3B1neutral lines (Figure 4G and Figure 4—figure supplement
1C). SF3B1 immunoprecipitation from fractions 24–25 resulted in co-precipitation of U2 snRNP com-
ponents SNRPB2 and SF3A3 (Figure 4—figure supplement 1F). U2 snRNA levels are known to track
with U2 snRNP levels, and we also did not observe a significant difference in U2 snRNA abundance
between SF3B1neutral and SF3B1loss lines (Figure 4I p=0.35, two-tailed t-test). Similarly, visualization
of U2 snRNP complexes using radiolabeled oligonucleotides complementary to the U2 snRNA did
not demonstrate differences in 17S U2 snRNP abundance in SF3B1loss cells (Figure 4J–K and Fig-
ure 4—figure supplement 1G, p=0.68).
These observations suggest that copy-loss of SF3B1 only modestly affects U2 snRNP abundance
but substantially decreases levels of U2 snRNP precursor complexes under steady-state conditions
(Figure 4L).
Figure 3 continued
with single-copy SF3B1 inactivation by CRISPR. (E) Scatterplot of SF3B1 mRNA and protein expression relative to diploid cell line Cal51 after
normalization to actin in a panel of breast cancer cell lines (p=0.0018, R2 = 0.772, regression line slope = 0.789). (F) SF3B1 immunoblot from SF3B1neutral
and SF3B1loss cells 4 days after TR-shSF3B1#5 induction by doxycycline. (G) Differences in proliferation 7 days after SF3B1 suppression (per CellTiter-
Glo, see Appendix Methods; red=high, blue=low), against the relative level of SF3B1 expression (assessed by qPCR; y-axis) in SF3B1neutral (left) or
SF3B1loss (right) cells expressing either shLacZ (origins of arrows) or shSF3B1 (ends of arrows). Origins with multiple arrows represent cell lines subject to
more than one SF3B1 shRNA. Each data point represents the mean from at least two replicate experiments. The dashed line represents the estimated
minimum threshold of SF3B1 expression required for survival. For all panels, *p<0.05 **p<0.01 ***p<0.001, and error bars represent ± SD.
DOI: 10.7554/eLife.23268.007
The following figure supplement is available for figure 3:
Figure supplement 1. Further characterization of SF3B1 as a CYCLOPS gene.
DOI: 10.7554/eLife.23268.008
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Figure 4. SF3B1 copy-loss selectively reduces the abundance of the SF3b complex. (A) Diagram of U2 snRNP assembly. (B–C) Glycerol gradient
fractionation of native whole-cell lysates probed by western blot in breast cancer cell lines and (D–E) isogenic cells generated by CRISPR. (F)
Quantification of SF3B1 immunoblots from glycerol gradient fractions 3–8, relative to fraction 3 (n = 3 for each group, see Appendix Methods). (G)
Serial dilution of pooled glycerol gradient fractions probed for SF3B1 by immunoblot. (H) (left) SF3B1 Native PAGE immunoblot of pooled glycerol
Figure 4 continued on next page
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SF3B1 suppression selectively reduces U2 snRNP abundance in
SF3B1loss cells
Partial suppression of SF3B1 leads to substantial reductions of U2 snRNP levels in SF3B1loss but not
SF3B1neutral cells. Although such suppression results in reduced SF3B1 levels in both SF3B1loss and
SF3B1neutral lines, only the SF3B1loss lines exhibit concomitant reductions in levels of U2 snRNP com-
ponents SF3A3 and SNRPB2 (Figure 5A). Decreases in SF3A3 and SNRPB2 were observed in glyc-
erol gradient fraction 25, corresponding to the U2 snRNP, most dramatically in SF3B1loss lines, and
to a lesser extent in one of the SF3B1neutral lines (Hs578T; Figure 5B). Furthermore, after SF3B1 sup-
pression, we detected both SF3B1 and SNRPB2 in Sephacryl-S500 fractions containing the >650 kDa
protein complexes in SF3B1neutral cells but not in SF3B1loss cells (Figure 5D–E and Figure 5—figure
supplement 1A). Quantitative PCR also indicated significantly reduced U2 snRNA expression after
SF3B1 partial suppression in SF3B1loss cells but not in SF3B1neutral cells (Figure 5F).
In contrast, suppression of SF3B1 in SF3B1neutral cells appears to substantially decrease levels of
SF3b, but not the U2 snRNP. SF3B1 suppression in SF3B1neutral cells only modestly reduced SF3B1 in
fraction 25 (Figure 5B and Figure 5—figure supplement 1B) but instead preferentially reduced
SF3B1 from fractions 4–6 (Figure 5C and Figure 5—figure supplement 1C). Further, no changes in
SF3A3 or SNRPB2 expression were observed in total protein from glycerol gradient inputs
(Figure 5A) or U2 snRNA expression (Figure 5F). Therefore, we determined if SF3B1 suppression in
SF3B1neutral cells phenocopies the reduced SF3b observed in unperturbed SF3B1loss cells. Indeed,
SF3B1neutral cells with SF3B1 suppression reduced SF3b levels in glycerol gradient fractions 3–6
approximately to the levels observed in SF3B1loss cells (Figure 5G). Taken together, these data sug-
gest that the elevated levels of the SF3b sub-complex in SF3B1neutral cells relative to SF3B1loss cells
appear to buffer SF3B1neutral cells from reductions in viability following partial SF3B1 suppression.
Consistent with Figure 4, SF3B1loss cells without SF3B1 suppression did not have significantly
lower levels of U2 snRNP in fraction 25 than SF3B1neutral cells (p=0.16, Figure 5—figure supplement
1D), suggesting SF3B1 copy-loss only reduces levels of the U2 snRNP following further depletion of
SF3B1.
The relative preservation of the U2 snRNP and larger complexes in SF3B1loss cells without SF3B1
suppression suggests existing SF3b inhibitors might not exploit the specific vulnerability exhibited
by SF3B1loss cells. SF3b inhibitors modulate U2 snRNP function or subsequent steps during splicing
catalysis (Corrionero et al., 2011; Folco et al., 2011; Roybal and Jurica, 2010), thereby altering
splicing leading to cell death. With similar U2 snRNP levels in SF3B1loss and SF3B1neutral cells, the
dose at which these effects would be expected to accrue might be similar.
We tested this hypothesis by exposing SF3B1neutral cell lines with partial SF3B1 suppression, and
controls to treatment with two SF3b-targeting compounds (Spliceostatin A, and Pladienolide B) and
with NSC95397, a compound reported to inhibit splicing activity by an SF3b-independent mecha-
nism (Berg et al., 2012). None of these exhibited increased effects on cells with partial SF3B1 sup-
pression. (Figure 5—figure supplement 1E–H). We also evaluated isogenic Cal51 cells with
engineered SF3B1 copy-loss and did not observe enhanced sensitivity of SF3B1loss-Cal51 cell lines
(Figure 5—figure supplement 1I).
Figure 4 continued
gradient fractions. (right) denaturing silver stain of total protein from the same pooled fractions as loading control. (I) Quantitative RT-PCR for U2
snRNA expression in three SF3B1neutral and three SF3B1loss breast cancer cell lines. (J) Native agarose gel of U2 snRNP complexes visualized with
radiolabeled 2’ O-methyl oligonucleotides complementary to the U2 snRNA. Nuclear extracts were generated from SF3B1control-Cal51 and SF3B1Loss-Cal51
cells. HeLa cell nuclear extracts (NE) ± ATP were used as controls. Representative image from triplicate experiments. (K) Densitometric quantification of
17S U2 snRNP bands in (J) presented as fold change relative to SF3B1control-Cal51 cells. Data are from three replicate experiments. (L) Model for changes
to U2 snRNP assembly associated with SF3B1 copy-loss. For all panels, *p<0.05, and error bars represent ± SD, ns = not significant.
DOI: 10.7554/eLife.23268.009
The following figure supplement is available for figure 4:
Figure supplement 1. SF3B1 copy-loss selectively reduces the abundance of the SF3b complex.
DOI: 10.7554/eLife.23268.010
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Partial SF3B1 suppression results in splicing defects in SF3B1loss cells
SF3B1 is well-established as a splicing factor (Gozani et al., 1998; Zhou et al., 2002), and intron
retention has been reported upon treatment of cells with SF3B1 inhibitors (Kotake et al., 2007)
while patients harboring SF3B1 mutations display alterations in alternative splicing (DeBoever et al.,
2015; Wang et al., 2011). We therefore quantified the extent of splicing disruption upon SF3B1
suppression in SF3B1neutral and SF3B1loss cells by RNA sequencing. RNA was isolated 4 days after
doxycycline treatment when SF3B1loss cells arrest in G2/M phase of the cell cycle (Figure 2F), but
have not initiated apoptosis (Figure 2G). We suppressed SF3B1 in SF3B1neutral cells to similar or
lower levels as seen at steady state in SF3B1loss cells, and suppressed SF3B1 in SF3B1loss cells to
even lower levels (Figure 3F and Figure 6—figure supplement 1A–B). We used juncBase
(Brooks et al., 2011) and a novel statistical framework to analyze 50,600 splice junctions for intron
retention in SF3B1neutral and SF3B1loss cells upon SF3B1 suppression from our RNA sequencing data.
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Figure 5. Reduced spliceosome precursors and U2 snRNP abundance upon SF3B1 suppression in SF3B1loss cells. (A) Western immunoblots without and
with SF3B1 suppression prior to glycerol gradient fractionation. (B) Western immunoblots from glycerol gradient fraction 25 (protein complexes >650
kDa). (C) Western immunoblots from pooled glycerol gradient fractions 4–6 (protein complexes ~150–450 kDa). (D) Immunoblot from lysates prior to gel
filtration chromatography. (E) Immunoblot of gel filtration fractions 18–26 (protein complexes >650 kDa) from lysates with SF3B1 suppression. (F)
Quantitative RT-PCR for U2 snRNA expression without and with SF3B1 suppression. (G) Glycerol gradient fractions from SF3B1neutral cells without and
with SF3B1 suppression compared to SF3B1loss without suppression. For all panels, TR-shSF3B1#5 was used. *p<0.05 **p<0.01 ***p<0.001.
DOI: 10.7554/eLife.23268.011
The following figure supplement is available for figure 5:
Figure supplement 1. Reduced spliceosome precursors and U2 snRNP abundance upon SF3B1 suppression in SF3B1loss cells.
DOI: 10.7554/eLife.23268.012
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Briefly, we calculated the ratio of percent spliced in (PSI) and spliced out read counts for each splic-
ing junction, but accounted for the probability that any single splicing junction may not be accurately
sampled in each cell line using a beta binomial distribution (see Appendix Methods).
All cells showed evidence of increased intron retention following SF3B1 partial suppression
(p<10 5), but splicing was significantly more affected in SF3B1loss cells. Upon SF3B1 suppression,
7353 transcripts in SF3B1loss cells showed evidence of significantly (q < 0.1) increased intron reten-
tion relative to SF3B1neutral cells, whereas only 454 transcripts showed evidence of increased intron
retention in the reverse direction (Figure 6A, p<10 1110).
We confirmed increased intron retention in SF3B1loss cells upon SF3B1 suppression by qPCR
amplifying selected introns of genes from the RNA sequencing analysis (Figure 6A). Introns were
significantly retained in all seven genes analyzed (AARS, CALR, DNAJB1, MKNK2, MYH9, RPS8 and
RPS18), which included DNAJB1, a gene previously known to be improperly spliced in cells treated
with SF3B1 inhibitors (Kotake et al., 2007), and cell essential genes AARS, RPS8 and RPS18
(Figure 6B).
The SF3b complex is known to regulate 3’ splice site selection (DeBoever et al., 2015). We
therefore analyzed 30,666 alternative 3’ splice sites from the RNAseq data in SF3B1neutral and
SF3B1loss cells. Reduced SF3B1 expression resulted in significantly more alternative 3’ splice site
selection in SF3B1loss cells (353 3’ splice junctions in SF3B1neutral vs. 1540 in SF3B1loss cells,
p<10 121, Figure 6C and Figure 6—figure supplement 1C). We also observed other alterations in
splicing. Alternative 5’ splice site selection occurred at a significantly higher rate upon SF3B1 sup-
pression in SF3B1loss cells (1411 junctions vs 317, p=910 165, Figure 6—figure supplement 1D).
We also observed increased dysregulation of cassette exon inclusion. The proportion of reads
including the cassette exon at each junction changed substantially after SF3B1 suppression in
SF3B1loss cells, but was less substantially altered in SF3B1neutral cells. (Figure 6—figure supplement
1E). We further validated these observations with independent assays for alternative splicing. Specif-
ically, the ratio between alternative long and short isoforms of MCL1 (that respectively do or do not
have anti-apoptotic functions) is known to be regulated by SF3B1 (Moore et al., 2010). After SF3B1
suppression, this ratio was significantly biased towards the short isoform in SF3B1loss cells relative to
SF3B1neutral cells (Figure 6D–E). Together, these data indicate that SF3B1 suppression more sub-
stantially dysregulates splicing of the transcriptome of SF3B1loss cells.
Spliceosome components, including SF3B1, are thought to assemble and function in sub-nuclear
compartments known as nuclear speckles (Spector and Lamond, 2011). Inhibition of splicing or
transcription has been shown to induce formation of enlarged ‘mega-speckles’ (Kotake et al., 2007;
Loyer et al., 1998). We therefore performed an unbiased quantification of the number and size of
SC-35+ speckles per nucleus using a custom image analysis pipeline with CellProfiler software
(Kamentsky et al., 2011).
SF3B1neutral cells did not display changes in SC-35+ speckles after SF3B1 partial suppression, but
SF3B1loss nuclei contained significantly fewer speckles and increased speckle area (Figure 6F–H).
The presence of defective alternative splicing, intron retention and formation of mega-speckles
uniquely in SF3B1loss cells after partial SF3B1 suppression further supports the gross defects in splic-
ing observed by RNA sequencing.
Moreover, upon SF3B1 suppression, 513 genes were differentially expressed at an FDR < 10% in
SF3B1loss cells and only 306 genes were differentially expressed in SF3B1neutral cells
(Supplementary file 1E, p<10 4, Fischer’s exact test). Gene set enrichment analysis revealed 24
KEGG pathways significantly enriched in SF3B1loss cells and only nine pathways altered in SF3B1neu-
tral cells (Figure 6I and Supplementary file 1F). We also identified a statistically significant core set
of 89 genes differentially expressed across all cell lines upon SF3B1 suppression regardless of SF3B1
copy number (p<10 4).
Upon SF3B1 expression, 348 genes were differentially expressed in SF3B1loss cells and 393 genes
were differentially expressed in SF3B1neutral cells, an insignificant difference (p=0.07,
Supplementary file 1G). We observed more differentially expressed genes in SF3B1loss cells from
SF3B1 suppression than from SF3B1 expression (p<0.0001), however, there was no difference
between the effects of SF3B1 suppression and expression in SF3B1neutral lines (p=0.7). Taken
together, these data indicate that partial SF3B1 suppression more severely impacts the transcrip-
tome of SF3B1loss cells.
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Suppression of SF3B1 reduces tumor growth in SF3B1loss xenografts
To test the effects of SF3B1 partial suppression in vivo, we generated xenografts from luciferase-
labeled SF3B1Loss-Cal51-1, SF3B1control-Cal51-1 cells and naturally occurring SF3B1neutral and SF3B1loss
cells (Cal51 and HCC1954, respectively) all containing TR-shSF3B1#3. Interventional studies were
performed where animals were placed on doxycycline upon detection of palpable tumors and vali-
dated for SF3B1 suppression (Figure 7—figure supplement 1A). SF3B1Loss-Cal51-1 and SF3B1control-
Cal51-1 cells generated tumors of similar volume in the absence of doxycycline (Figure 7A; p=0.7,
repeated measures ANOVA). However, partial suppression of SF3B1 reduced the growth of
(Figure 7B–C) and number of proliferative Ki67+ cells in (Figure 7D–E) xenografts from SF3B1Loss-
Cal51-1 cells but not SF3B1control-Cal51-1 cells (p=0.001 for both assays). Similarly, reduced tumor
growth was observed in naturally occurring SF3B1loss HCC1954 xenografts and not in SF3B1neutral
Cal51 xenografts (Figure 7F).
Compounds that induce degradation of SF3B1 selectively kill SF3B1loss
cells
The lack of efficacy of small molecule splicing modulators targeting SF3B1 prompted us to evaluate
other compounds that could pharmacologically target the SF3B1 CYCLOPS dependency. Deubiquiti-
nase inhibitors (DUBi’s) are a class of compounds that increase protein degradation by preventing
the removal of ubiquitin from substrates, thereby enhancing target protein degradation by the pro-
teasome. We first sought evidence for SF3B1 ubiquitination by treating cells with the proteasome
inhibitor, epoxomicin, to increase the accumulation of ubiquitinated proteins. Immunoprecipitation
of SF3B1 in denaturing conditions after epoxomicin treatment resulted in the detection of ubiquiti-
nated SF3B1 (Figure 8—figure supplement 1A–B). Furthermore, proteasome inhibition by MG-132
increased SF3B1 protein levels, suggesting SF3B1 is regulated by the proteasome (Figure 8—figure
supplement 1C).
To determine if DUBi’s could decrease SF3B1 protein expression, we evaluated seven candidate
DUBi’s for reduced SF3B1 expression by western blot (data not shown) and identified three DUBi’s
with the ability to reduce SF3B1 protein levels within 24 hr (Figure 8A). Of the 3 DUBi’s that enhance
SF3B1 degradation, one semi-selective DUBi b-AP15 (D’Arcy et al., 2015), demonstrated enhanced
sensitivity in SF3B1loss cells, and also cells with reduced SF3B1 expression by RNAi (Figure 8B). The
enhanced sensitivity in SF3B1loss cells or cells with reduced SF3B1 expression by RNAi was not
observed upon treatment with SJB3-019A or the pan-DUBi, PR-619 (Figure 8—figure supplement
1D), suggesting inhibition of a specific DUB enzyme may mediate this effect. SF3B1Loss-Cal51 cells
also had more Annexin V apoptotic cells than SF3B1control-Cal51 cells when treated with nanomolar
concentrations of b-AP15 (Figure 8C). Immunoblots for SF3B1 after b-AP15 treatment revealed
decreased SF3B1 only occurred in SF3B1Loss-Cal51-2 cells (Figure 8D and Figure 8—figure supple-
ment 1E). These data suggest the enhanced sensitivity may be due, in part, to reduction of SF3B1 in
SF3B1Loss-Cal51 cells.
Treatment of cells with b-AP15 resulted in splicing alterations preferentially in SF3B1loss cells. We
determined the effect of b-AP15 treatment on previously identified splicing alterations that result
Figure 6 continued
(SF3B1neutral n = 3, SF3B1loss n = 3, averaged from TR-shSF3B1#3 and TRshSF3B1#5. SF3B1control-Cal51 and SF3B1Loss-Cal51 n = 2 each, averaged from TR-
shSF3B1#3). (C) Statistical significance of alternative 3’ splice site selection (see Materials and methods) across 3’ splice junctions (dots) in
SF3B1neutral (red) and SF3B1loss cells (blue) after SF3B1 suppression (as in panel A). (D) Representative RT-PCR from SF3B1neutral and SF3B1loss cells after
SF3B1 knockdown. ‘c’ represents LacZ control hairpins, ‘sh’ represents shSF3B1#4. Arrows represent product sizes for MCL-L and MCL-S. (E)
Densitometric quantification of the ratio of MCL1-S:MCL1-L, relative to shLacZ-expressing controls (mean ± SD, n = 3 per group averaged from
shSF3B1#3, and #4). (F) Immunofluorescent images of nuclear speckles by anti-SC35 (SRSF2) staining. Scale bar = 5 uM. (G) Quantification of number of
nuclear speckles and (H) speckle area per cell across at least 100 nuclei. For (F–H) TRshSF3B1#5 was used. (I) Number of differentially expressed genes
upon SF3B1 suppression (q < 0.1) and the number of enriched KEGG pathways amongst indicated gene set (q < 0.05). For all panels, *p<0.05 **p<0.01
***p<0.001.
DOI: 10.7554/eLife.23268.013
The following figure supplement is available for figure 6:
Figure supplement 1. Partial SF3B1 suppression results in splicing defects in SF3B1loss cells.
DOI: 10.7554/eLife.23268.014
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Figure 7. SF3B1 suppression inhibits tumor growth in vivo. Luminescent quantification of xenograft growth from SF3B1control-Cal51-1 (black) and
SF3B1Loss-Cal51-1 (red) tumors (A) without doxycycline (n = 4) and (B) with doxycycline (n = 17) using TR-shSF3B1 #3. (C) Representative animal images
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each tumor,  3 tumors per group (see Materials and methods). (E) Representative Ki67 immunohistochemistry images of xenografts quantified in panel
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DOI: 10.7554/eLife.23268.015
The following figure supplement is available for figure 7:
Figure supplement 1. SF3B1 suppression inhibits tumor growth in vivo.
DOI: 10.7554/eLife.23268.016
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Figure 8. Deubiquitinase inhibitor b-AP15 can induce SF3B1 degradation and selectively kill SF3B1loss cells. (A) SF3B1 immunoblot after DUBi
treatment of the SF3B1neutral cell line, Cal51, at the indicated time points. (B) b-AP15 dose response curves in isogenic cell contexts. SF3B1control-Cal51
and SF3B1Loss-Cal51 or SF3B1neutral cells with or without doxycycline expressing TR-shSF3B1 #5, to phenocopy the reduced SF3B1 expression observed in
SF3B1loss cells, were assayed 48 hr after b-AP15 treatment. (C) Percent of Annexin V positive cells 24 hr after b-AP15 treatment in SF3B1control-Cal51 and
SF3B1Loss-Cal51 cells. (D) SF3B1 immunoblot 48 hr after treatment with 500 nM b-AP15 in SF3B1control-Cal51-2 and SF3B1Loss-Cal51-2 cells. (E) qPCR for a
single intron within the indicated gene with 550 nM b-AP15 or DMSO control (SF3B1neutral n = 2, SF3B1loss n = 2, averaged from SF3B1control-Cal51 and
SF3B1Loss-Cal51 cells). (F) Schematic of luciferase reporter constructs used in (G). Yellow rectangles represent luciferase protein coding regions. Angled
black line represents the location of the intron. (G) Fold change in luciferase splicing reporter signal after b-AP15 treatment. Data represented as the
ratio of spliced luciferase signal (Luc-I) to luciferase ORF signal (Luc-ORF) relative to their respective DMSO luciferase signal. DMSO treatment (black),
350 nM b-AP15 (light red) and 550 nM b–AP15 (dark red). (H) b-AP15 dose response in SF3B1control-Cal51-2 and SF3B1Loss-Cal51-2 cells expressing GFP
(black) or SF3B1 (blue). For all panels, *p<0.05 **p<0.01 ***p<0.001.
DOI: 10.7554/eLife.23268.017
The following figure supplement is available for figure 8:
Figure supplement 1. Deubiquitinase inhibitor b-AP15 can induce SF3B1 degradation and selectively kill SF3B1loss cells.
DOI: 10.7554/eLife.23268.018
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from SF3B1 suppression. SF3B1loss cells but not SF3B1neutral cells exhibited increased intron reten-
tion in CALR, RPS8 and DNAJB1 after treatment with 550 nM b-AP15 (Figure 8E). We also gener-
ated stable luciferase expressing cell lines with either a luciferase gene interrupted by a chimeric
globin/immunoglobulin intron (Luc-I), or a luciferase open reading frame that does not require splic-
ing as a control (Luc-ORF) (Figure 8F) (Younis et al., 2010). b-AP15 treatment resulted in a dose-
dependent decrease in the ratio of Luc-I:Luc-ORF in SF3B1loss-Cal51-2 cells, but not SF3B1control-Cal51-2
cells, suggesting b-AP15 induced SF3B1 degradation may mediate splicing reporter loss of function
(Figure 8G). In contrast, b-AP15 also enhanced SF3B1control-Cal51-2 splicing reporter signal. Lastly,
rescue experiments in which we expressed exogenous SF3B1 increased the concentration of b-AP15
required to impact cell viability in SF3B1loss cells, but did not affect the sensitivity of SF3B1control-
Cal51-2 cells (Figure 8H).
Taken together, these results suggest that the DUBi, b-AP15, can decrease SF3B1 stability with
increased sensitivity in SF3B1loss cells. They also suggest DUBi’s as a potential class of small mole-
cules to be used as a general approach to target candidate CYCLOPS gene dependencies identified
here.
Discussion
Our analysis indicates that CYCLOPS vulnerabilities are the most enriched class of copy-number
associated cancer vulnerabilities, and a focused analysis of this class of vulnerabilities identified 124
candidate CYCLOPS genes. In previous work involving 86 cell lines (Nijhawan et al., 2012), we had
identified 55 candidate CYCLOPS genes at a q < 0.25 significance threshold. Here, we evaluated
over twice as many cell lines (179), generating more than twice as many candidate CYCLOPS genes
(124) at a more stringent significance threshold (q < 0.1). We also identified trans gene dependen-
cies associated with copy gain, but the regions of copy gain are often large and contain many genes.
As a result, it is difficult to assign a specific gene within the gained region as causing the depen-
dency when gained. Nonetheless these classes of copy number associated gene dependencies war-
rant further investigation.
Our enhanced ability to detect candidate CYCLOPS genes with larger sample sizes suggests that
analysis of additional lines is likely to reveal more candidates. For example, we were unable to iden-
tify tumor-type specific CYCLOPS genes due to the relatively small numbers of cell lines screened in
each cell lineage. In addition, detection of CYCLOPS vulnerabilities requires partial gene suppres-
sion, in which the optimal level of suppression may vary by gene. Among SF3B1 shRNAs, ~50% sup-
pression was achieved. We do not know the extent to which the shRNAs used in Project Achilles
matched the required levels to expose CYCLOPS vulnerabilities across other genes. These limita-
tions suggest expanding RNAi viability screens to include more cancer cell lines and shRNAs may
yield further CYCLOPS dependencies.
The candidate CYCLOPS genes we identified shared the following features: (1) consistent expres-
sion across normal tissues, (2) altered expression when affected by copy-number alterations suggest-
ing lack of feedback regulation, (3) location in genomic regions that frequently undergo copy-loss.
These features may predispose genes towards meeting CYCLOPS criteria. However, we cannot
exclude the possibility that CYCLOPS genes with different features exist but were not identified due
to the limitations of the screening data or analyses.
Components of the spliceosome were the most frequently represented genes among CYCLOPS
candidates, with 20 representatives, including SF3B1. The spliceosome, which is essential for cell sur-
vival, has previously been identified as a therapeutic target in cancer (Kaida et al., 2007;
Kotake et al., 2007; Mizui et al., 2004; Webb et al., 2013). Also, the magnitude of SF3B1 copy-
loss required to unveil the SF3B1 CYCLOPS dependency (e.g. single copy loss in a tetraploid cell)
will require further study. Our work further substantiates the importance of the spliceosome as a
therapeutic target in cancer, and suggests CYCLOPS vulnerabilities as a possible mechanism of
dependency.
Mutation of the spliceosome components SF3B1 and U2AF1 are recurrent driver events in many
cancer types including chronic lymphoblastic leukemia, myelodysplastic syndrome, uveal melanoma
and breast cancer (Ellis et al., 2012; Harbour et al., 2013; Imielinski et al., 2012;
Papaemmanuil et al., 2011; Wang et al., 2011; Yoshida et al., 2011). Recent evidence demon-
strated that mutations in SF3B1 and SRSF2 can confer preferential sensitivity to chemical modulation
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of the spliceosome (Lee et al., 2016; Obeng et al., 2016). In contrast, we observed partial copy-
loss of SF3B1 and U2AF1, likely the result of passenger copy-number alterations, resulted in
CYCLOPS vulnerabilities. Consistent with our observations, recent studies of Sf3b1+/- mice suggest
that partial SF3B1 loss does not generate haploinsufficient phenotypes (Matsunawa et al., 2014;
Wang et al., 2014) in contrast to previous data (Visconte et al., 2012). Our observation that ESS1,
a SF3B1K666N mutant cell line, was sensitive to partial SF3B1 suppression is consistent with a prior
report that SF3B1-mutant cancer cells were found to depend on remaining wild-type copy
(Zhou et al., 2015). Mutant SF3B1 is also associated with aberrant 3’ splice site selection and ~50%
rate of nonsense mediated decay in processed transcripts, suggesting that those transcripts exhibit
partial loss of function (Darman et al., 2015). Taken together, SF3B1 mutations may be associated
with CYCLOPS dependencies, at least in some cases. Therefore, it is possible that similar approaches
to targeting the spliceosome can be exploited in SF3B1-mutant and SF3B1loss cancers. However, it is
also possible that alternative strategies will be required for SF3B1-mutant and SF3B1loss cancers,
due to their different effects on spliceosome assembly and activity.
We found that partial SF3B1 suppression is tolerated in SF3B1neutral cells due to a stable pool of
SF3b sub-complex outside of the U2 snRNP. To our knowledge, this is the first observation of such a
pool of SF3b, and raises the possibility that SF3b has functions in addition to its role in the U2
snRNP. Precedence exists for such functions as SF3B1 is reported to be a component of the poly-
comb repressor complex and also directly associates with nucleosomes (Isono et al., 2005;
Kfir et al., 2015). We also observed decreased protein levels of SNRPB2, SF3A3 and the U2 snRNA
in SF3B1loss cells after SF3B1 suppression (Figure 5A and F). It is possible that due to the decreased
amount of assembled 17S U2 snRNP, the U2 precursor complexes are less stable and degraded to
maintain proper U2 snRNP stoichiometry in SF3B1loss cells. Although these experiments were per-
formed prior to detection of apoptosis, we cannot exclude the possibility that decreased U2 precur-
sor complexes are a result of decreased cell viability beyond the level of detection.
Small molecule inhibitors of SF3B1, and the spliceosome in general, are an emerging class of
anti-neoplastic agents. The finding that many candidate CYCLOPS genes are splicing factors sug-
gests further efforts should be paid to identifying CYCLOPS vulnerabilities that can be exploited by
spliceosome inhibitors.
In the case of SF3B1, we find that SF3B1 copy-loss reduces the levels of the SF3b complex, but
not assembled U2 snRNP, which suggests that inhibitors of the assembled U2 snRNP will not ade-
quately distinguish between SF3B1loss and SF3B1neutral cells. This includes most current inhibitors of
SF3B1 (Corrionero et al., 2011; Folco et al., 2011; Roybal and Jurica, 2010). Understanding which
SF3B1 complexes are bound by these compounds, and how they affect the stability, assembly, or
function of the U2 snRNP, will be important to glean mechanistic insight into the landscape of small
molecule modulation of SF3B1.
More generally, many CYCLOPS vulnerabilities are unlikely to be exploited by compounds that
directly inhibit CYCLOPS gene enzymatic activity. Most of the candidate CYCLOPS genes we identi-
fied are not enzymes. Many of them are components of multi-protein complexes. One approach to
exploiting these vulnerabilities may be to disrupt the incorporation of the proteins encoded by such
CYCLOPS genes into these larger complexes. Another approach may be to reduce levels of protein
encoded by CYCLOPS genes, either by interfering with the transcription of these genes
(Arrowsmith et al., 2012; Kwiatkowski et al., 2014) or by enhancing protein degradation
(Bondeson et al., 2015; D’Arcy et al., 2015; Winter et al., 2015). An advantage to CYCLOPS tar-
gets such as SF3B1 is that only moderate (~50%) reductions in protein levels need to be achieved to
take advantage of the vulnerability.
Finally, we evaluated DUBi’s as a potential small molecule to target the SF3B1 CYCLOPS vulnera-
bility. We found that the DUBi b-AP15 could reduce SF3B1 protein levels and preferentially target
SF3B1loss cells. A derivative of b-AP15, VLX1570, is already in use in humans (Trial ID:
NCT02372240). Our results indicate SF3B1 copy number should be tested as a potential biomarker
of response for patients treated with this compound.
Although b-AP15 specifically suppressed growth of cells with loss of SF3B1, it is possible other
DUBi’s would be even more specific. There are approximately 90 DUBs in humans (Nijman et al.,
2005), and the DUBi’s we tested are relatively non-selective. Further investigation of the specific
DUBs that support SF3B1 protein expression would enable identification DUBi’s whose effects are
more targeted to the SF3B1 dependency.
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The finding that a DUBi specifically suppresses growth of cells with loss of SF3B1 also supports
the use of DUBi’s to target any of the 124 candidate CYCLOPS genes we identified, representing a
potential paradigm for treating cancers based upon non-oncogenic genetic events.
Materials and methods
Analysis of genome-wide copy-number associated cancer dependencies
Gene-level relative copy-numbers were downloaded from the CCLE portal (http://www.broadinsti-
tute.org/ccle, data version 4/06/2012) totaling 23,124 genes. Gene-level dependencies were
obtained for 214 cell lines from Project Achilles (version 2.4.3). Of the 214 cell lines, only 179 had
corresponding copy-number data and were used for subsequent analyses. ATARiS gene dependency
scores were used to estimate the effect of shRNA-induced gene suppression on cell viability
(Shao et al., 2013) totaling 8724 gene dependencies. Pearson correlation coefficients and associ-
ated p-values were calculated for the association of viability after suppression of each gene with the
copy number of all genes. P-values were corrected for multiple hypotheses using the Benjamini-
Hochberg method (Benjamini and Hochberg, 1995). We considered associations between copy-
numbers of every gene in the genome and dependencies of every gene with ATARiS scores. Large
copy-number events affecting many neighboring genes often generated identical significant copy-
number:gene dependency associations for copy-numbers associated with multiple genes. We con-
sidered these to reflect a single gene whose copy-number was responsible for the association. When
the gene dependency was one of the genes contained within the copy-number altered region, we
nominated that gene as the source of the association. Likewise, if a gene dependency reflected a
paralog of a gene within the copy-number altered region, we nominated its paralog as the depen-
dency-associated gene within the altered region.
CYCLOPS analysis
We determined the significance of differences in ATARiS scores between copy-neutral and –loss
lines for every gene by comparing the observed data to data representing random permutations of
copy-number class labels, each maintaining the number of cell lines and lineage distribution in each
class. Copy-number classes were assigned as copy-loss for cells with log2 relative copy number
ratios   0.35 and copy-neutral otherwise. Genes for which fewer than two cell lines exhibited copy
loss were excluded from the analysis.
Generation of heterozygous SF3B1loss cells by CRISPR-Cas9
For SF3B1Loss-Cal51-1 cells, sgRNAs targeting the first constitutively expressed coding exon of SF3B1
(exon 2) were designed with the aid of a web-based application (http://crispr.mit.edu/). Sense and
anti-sense oligonucelotides were annealed and cloned into BbsI site of pX458 (Addgene) and veri-
fied by Sanger sequencing. Single GFP+ cells were sorted by FACS and plated at low density for sin-
gle cell cloning. SF3B1control-Cal51-1 cells were processed identically, but did not have inactivating
SF3B1 mutations. (See supplementary information for further details.)
For SF3B1Loss-Cal51-2 cells, a Cas9 construct co-expressing two sgRNAs and GFP was used to
delete a 57 kb region encoding SF3B1. The guide RNA targeting the 5’ upstream of SF3B1 used a
mismatch from a heterozygous SNP (rs3849362) in Cal51 to bias towards mono-allelic deletion of
SF3B1. Single GFP+ cells were plated as described above and expanded. One of these was vali-
dated by PCR to harbor a 57 kb deletion encoding SF3B1. This was designated ‘SF3B1Loss-Cal51-2’ for
subsequent experiments. Another one of these was found by PCR not to harbor this deletion and
was designated as the control cell line for subsequent experiments (‘SF3B1control-Cal51-2’).
Glycerol gradient sedimentation
Glycerol gradient sedimentation was performed as previously described (Hartmuth et al., 2012)
with slight modifications for use with whole-cell lysates. Briefly, 10–30% glycerol gradients were
formed by layering 10% glycerol gradient buffer (20 mM Hepes-KOH (pH 7.9), 150 mM NaCl, 1.5
mM MgCl210% glycerol) on top of a 30% glycerol buffer with identical salt concentrations. Gradients
were formed using a Gradient Station (Biocomp Instruments). Cells were lysed in ‘IP lysis buffer’ (50
mM Tris, 150 mM NaCl and 1% Triton X-100). 400 uL containing 1–3 mg of crude lysate was loaded
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per gradient in SW55 centrifuge tubes and spun at 55,000 RPM for 3.5 hr at 4C. A total of 25 200 uL
fractions were collected by manually pipetting from the top of the gradient. Recombinant proteins
of known mass were run in parallel gradients as controls.
Gel filtration chromatography
Sephacryl S-500 (17-0613–05, GE Healthcare) columns were packed into a 50  1.5 cm column and
equilibrated with column buffer (10 mM Tris, 60 mM KCl, 25 mM EDTA, 1% Triton X-100 and 0.1%
sodium azide). Whole-cell lysates were collected in IP lysis buffer as described above and incubated
with 0.5 mM ATP, 3.2 mM MgCl2 and 20 mM creatine phosphate (di-Tris salt) for 20 min at 30C to
dissociate multi-snRNP spliceosomal complexes. 2 mL of lysate containing 5 mg of protein was
loaded on columns and 90 1.5 mL fractions were collected overnight at 4C.
RNA sequencing analysis
Total RNA was extracted and treated by DNAse digestion. RNA quality was determined by bioana-
lyzer (Agilent) and samples with RIN values >7 were used for sequencing. mRNAs were enriched
with the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England BioLabs, #E7490S) and
library preparations were performed with the NEBNext Ultra Directional RNA Library Prep Kit (New
England BioLabs, #E7420S). 75 bp paired reads were generated using a NextSeq 500 sequencer
(Illumina). Approximately 50 million reads per sample were generated. FASTQ files were aligned
using TOPHAT v1.4 with parameters ‘–mate-inner- dist 300 –mate-std-dev 500 –no-sort-bam –no-
convert-bam -p 4’. JuncBase was used to identify read counts at splice junctions (see Appendix
Methods).
Generation of xenografts and growth assessment
All animal husbandry was done with the approval of the Dana-Farber Cancer Institute IACUC. 1 
106 SF3B1control-Cal51-1 or SF3B1Loss-Cal51-1 cells expressing TR-shSF3B1 #3 were subcutaneously
injected into opposing flanks of nude mice (Foxn1 nu/nu, Harlan). Animals were randomized to control
group or doxycycline treatment after detection of a palpable tumor on either flank. Mice in the
doxycycline treatment arm were continuously fed a doxycycline diet (2000 ppm). Mice were sacri-
ficed at the end of the experiment, or when endpoints were reached based on failure to thrive
according to IACUC recommendation. Repeated measures two-way ANOVA was used to assess
significance.
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Appendix
We use the following definitions:
Somatic copy-number alterations (SCNAs):
Somatic changes in the number of copies of a DNA sequence that are observed in cancer
cells but not their paired germline DNA.
Gene dependency:
A gene whose suppression results in a loss of fitness for a particular cell context.
Copy-number associated gene dependency:
A gene dependency among cells that share a copy-number alteration at a given locus. In the
case of cancer, most of these copy-number alterations will be somatic (SCNAs).
We also distinguish between the following classes of copy-number associated gene
dependencies:
1. Cis copy-number associated gene dependencies: Here, the dependency on a gene is associ-
ated with the copy number of that gene. This can take two forms:
a. Cancer cells can be especially vulnerable to suppression of a gene when it is amplified.
This class of dependencies comprises oncogene addiction-induced dependencies, which
result from amplifications of a target gene whose increased expression is important in
maintaining cancer cell survival. One example is EGFR amplifications in lung cancer.
b. Cancer cells can depend on a gene within a region of partial copy loss. For this class,
reduced copy-number of the gene imparts sensitivity to further suppression of that same
gene. This is the CYCLOPS (Copy-number alterations Yielding Cancer Liabilities Owing to
Partial losS) class.
2. Trans copy-number associated gene dependencies: Here, the dependency on a gene is asso-
ciated with the copy number of a different gene.
a. Amplifications of a region can impart sensitivity to suppression of a gene outside the
gained region. Currently, we know of no genes in this class.
b. Copy loss of a gene can impart sensitivity to suppression of a different gene. Such depen-
dencies can occur if deletion of one gene from a paralogous pair of genes renders cells
sensitive to suppression of the remaining paralog.
Supplemental experimental procedures
Classification of length and amplitude for copy number alterations
For relative log2 normalized copy number data analyzed from 10,570 tumors from TCGA
(Zack et al., 2013), the following thresholds were used for copy number classification:
homozygous loss log2values < 1.2, hemizygous loss log2   0.35. For cancer cell lines used
in functional studies: copy-loss cells had log2 copy number   0.35, and copy neutral cells
had log2 copy number > 0.2 and <0.2.
Analysis of the location of CYCLOPS genes on chromosome arms
with known tumor suppressors
Deleted tumor suppressor genes were obtained from the combined lists from previous studies
(Beroukhim et al., 2010; Zack et al., 2013). Among 8131 genes assessed by Achilles, 5546
were on chromosome arms with at least one deleted tumor suppressor gene, including 73 of
the 124 candidate CYCLOPS genes. A two-sided Fisher’s exact test was used to determine
the significance of enrichment of CYCLOPS genes on arms shared with tumor suppressors.
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Analysis of candidate CYCLOPS gene and their overlap with
Marcotte et al. (2016) shRNA viability screen
A complete list of genes analyzed for increased sensitivity upon partial copy loss was kindly
shared by Azin Sayad and Benjamin Neel [see Table S6C in Marcotte et al. (2016). A total
of 8008 genes were analyzed in both studies, including 103 of the 124 candidate CYCLOPS
genes we identified. We used the authors’ determinations of which genes exhibited
statistically significant associations between dependency and copy loss, taking p<0.05 as the
significance threshold. The overall significance of overlap between candidate CYCLOPS
genes in our study and (Marcotte et al., 2016) was determined using a Fisher’s Exact test
with a two-sided p-value.
Analysis of gene expression across normal tissues
RNA sequencing data were downloaded from the GTEX database (http://www.gtexportal.org/
home/). For every gene in the genome, we calculated the expression variance across all
samples and ranked the variance against the 20 genes with the most similar average
expression level. These ranks served as a nearest-neighbors normalized measure of
expression variance.
Tissue culture
Human cancer cell lines were maintained in RPMI-1640 supplemented with 10% fetal bovine
serum and 1% penicillin and streptomycin and were assayed to be free of mycoplasma. Non-
transformed MCF10A and HMEC cells were cultured in Mammary Epithelial Growth Medium
(CC-3150, Lonza). For cells expressing tetracycline-regulated shRNAs, tetracycline-approved
fetal bovine serum (Clonetech) was used. Cell lines were original purchased from ATCC or
DSMZ. All cell line identities were confirmed using genetic profiling using polymorphic short
tandem repeat (STR) loci at the Dana-Farber molecular diagnostics laboratory. No commonly
misidentified cell lines defined by the International Cell Line Authentication Committee have
been used in these studies.
Correlation analysis of copy-loss of SF3b genes with cell
dependencies upon suppression of other SF3b complex genes
We determined the relative copy number and ATARiS gene dependency scores after
knockdown of each SF3b complex member across the same 179 cell lines used in the
CYCLOPS analysis. We performed linear regression analysis for copy number of each SF3b
complex gene with knockdown of every SF3b component. One-sided p-values were
calculated for association of sensitivity to suppression with gene loss for all intra-SF3b
complex comparisons. Samples were excluded if they harbored co-deletion of the two
genes used to generate the correlation.
Quantitative and reverse transcription PCR
RNA was extracted using the RNeasy extraction kit (Qiagen) and subjected to on-column DNase
treatment. cDNA was synthesized with the Superscript II Reverse Transcriptase kit (Life
Technologies) with no reverse transcriptase samples serving as negative controls. Gene
expression was quantified by Power Sybr Green Master Mix (Applied Biosystems). Primers
for all genes were determined to be equally efficient over five serial two-fold dilutions. Gene
expression values were normalized to ACTB and the fold change calculated by the DDCt
method. For quantification of the U2 snRNA, the above method was used except total
cellular RNA was extracted with Trizol (Life Technologies). For primer sequence information
see Supplementary file 1H.
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shRNAs targeting SF3B1
Lentiviral expression constructs for shRNA-mediated suppression of SF3B1 were obtained
through the RNAi-consortium (http://www.broadinstitute.org/rnai/public/). The clone ID’s
and names used in our studies are as follows: shSF3B1 #2 (TRCN0000320576), shSF3B1 #3
(TRCN0000320566), shSF3B1 #4 (TRCN0000350273), shSF3B1 #5 (TRCN0000320636). For
PHF5A, the clone ID’s and names used were: shPHF5A-78 (TRCN0000074878) and
shPHF5A-79 (TRCN0000074879). For constitutive and inducible vectors, we respectively
used the pre-existing control hairpins shLacZ and shLuciferase (Nijhawan et al., 2012).
Generation of Inducible SF3B1 shRNA expression system.
Sense and anti-sense oligonucleotides were annealed and cloned into the AgeI and EcoRI
restriction sites of the pLKO-Tet-puro vector (Addgene, plasmid #21915). The
oligonucleotide sequences were:
TR-shSF3B1#3 (sense) 5’-
CCGGCAACTCCTTATGGTATCGAATCTCGAGATTCGATACCATAAGGAGTTGTTTTTG,
TR-shSF3B1#3 (anti-sense) 5’-
AATTCAAAAACAACTCCTTATGGTATCGAATCTCGAGATTCGATACCATAAGGAGTTG,
TR-shSF3B1#5 (sense) 5’-
CCGGCCTCGATTCTACAGGTTATTACTCGAGTAATAACCTGTAGAATCGAGGTTTTTG,
TR-shSF3B1#5 (anti-sense) 5’-
AATTCAAAAACCTCGATTCTACAGGTTATTACTCGAGTAATAACCTGTAGAATCGAGG
Additional information for the generation of heterozygous
SF3B1loss cells by CRISPR-Cas9
Oligonucleotide sequences for SF3B1Loss-Cal51-1 were as follows: 5’
CACCGCATAATAACCTGTAGAATCG (forward), 5’AAACCGATTCTACAGGTTATTATGC
(reverse). pX458 was transfected with LipoD293 (SignaGen) into the diploid breast cancer
cell line, Cal51.19 monoclonal cell lines were genotyped for Cas-9 induced mutations by
Sanger sequencing cloned PCR products. All monoclonal lines had either no mutations or
harbored biallelic mutations in SF3B1. The genotypes of the Cal51 CRISPR cell lines used
from this method of generation were: SF3B1delT36/delT36 (SF3B1control-Cal51-1) and SF3B1delT36/
A23fsX20 (SF3B1Loss-Cal51-2). Copy number profiles from the two lines were characterized by
SNP array. No SCNAs were detected as a result of single cell cloning (data not shown).
Oligonucleotides for SF3B1Loss-Cal51-2 cells were cloned in a similar fashion as SF3B1Loss-Cal51-
1 in pX458 (with BbsI overhangs). The sequences are as follows: For the 5’ guide targeting
SNP, 5’ CACCGCGCATTATAGATTATGGCCC (forward) and 5’
AAACGGGCCATAATCTATAATGCGC (reverse). For the 3’ targeting guide:
5’CACCGCGGAGTTTCATCCGTTACAC (forward), AAACGTGTAACGGATGAAACTCCGC
(reverse)
Cellular growth assays
Cells were plated in 96 well plates at 1000 cells per well. Cell number was inferred by ATP-
dependent luminescence by Cell Titer Glo (Promega) and normalized to the relative
luminescence on the day of plating. For short-term lentiviral infections, cells were infected
24 hr prior to plating. Relative proliferation was calculated as the fold change in ATP
luciferase luminescence units from Cell Titer Glo assays relative to shLacZ expressing cells
seven days after shRNA infection (Figure 3G).
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GFP competition assays
Oligonucleotides encoding LacZ or SF3B1 shRNA#4 hairpin sequences were annealed and
cloned into the pLKO.1 derivative vector TRC047 (pLKO.3pgw) and verified by Sanger
sequencing. Cells were infected with serial dilutions of virus to achieve ~50% GFP-positive
cells. Cells with approximately equivalent ratios of GFP-positive and negative cells were
assayed by flow cytometry 3 days post infection and at subsequent time-points. The fold
change in GFP+ cells was normalized to the percentage present 3 days after infection. For
competition assays re-introducing exogenous SF3B1, we expressed a human codon-
optimized SF3B1 by lentivirus. Cells were infected as described above and treated with
doxycycline two days after infection.
Propidium iodide cell viability assays
Cells were treated with either short-term lentiviral infection or tetracycline-inducible SF3B1
shRNAs. After treatment, cells were trypsinized and pelleted including any cells in
suspension. Cells were resuspended in propidium iodide viability staining solution (1x PBS,
1% BSA, 2.5 ug/mL propidium iodide) and quantified by live-cell flow cytometry. The change
in viability was normalized to the percent of viable cells quantified on the first day of the
assay.
Determination of cell cycle distribution by propidium iodide
Cells were trypsinized, washed, and fixed with ice-cold 70% ethanol for a minimum of 15 min at
4C. Cells were incubated in propidium iodide cell cycle staining solution (1x PBS, 1% BSA,
50 ug/mL propidium iodide, 100 ug/mL RNAse A) for 15 min and analyzed by flow
cytometry. Debris and aggregates were gated out and cell cycle stage was quantified using
Modfit (Varity Software House).
Annexin-V apoptosis assays
Cellular apoptosis was quantified by live-cell flow cytometry using Alexa-Fluor 488 conjugated
Annexin-V (Life Technologies) and propidium iodide. Cells were incubated in Annexin
binding buffer containing propidium iodide (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2,
2.5 ug/mL propdium iodide) for 15 min, washed and resuspended in FACS buffer (1x PBS,
1% BSA and 50 mM EDTA). Determination of the stage of apoptosis by gating was as
follows: viable cells (Annexin-V /PI ), early apoptosis (Annexin-V+/PI ), late apoptosis
(Annexin-V+/PI+), and dead cells (Annexin-V /PI+).
Western blotting
For denaturing protein immunoblots, cells were washed in ice cold PBS and lysed in 1x RIPA
buffer (10 mM Tris-Cl Ph 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% SDS and 140 mM NaCl)
supplemented with 1x protease and phosphatase inhibitor cocktail (PI-290, Boston
Bioproducts). Lysates were sonicated in a bioruptor (Diagenode) for 5 min (medium
intensity) and cleared by centrifugation at 15000 x g for 15 min at 4C. Proteins were
electrophoresed on polyacrylamide gradient gels (Life Technologies) and detected by
chemiluminescence. For native western blotting, cells were washed in ice cold PBS and lysed
in 1x sonication buffer (10% Glycerol, 25 mM HEPES pH 7.4, 10 mM MgCl2) supplemented
with protease and phosphatase inhibitors. Coomassie blue native PAGE western blots were
run according the manufacturer’s instructions (Life Technologies).
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Quantification of western blots by densitometry
Immunoblot exposures were quantified using ImageJ (Schneider et al., 2012) as previously
described (http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-
image-j/). For early glycerol gradient fractions, pixel density histograms and an area under
the curve (AUC) were calculated for each western blot band. Each western band AUC was
normalized relative to loading control AUCs and then expressed as the fold change relative
to glycerol fraction #3 (for Figure 4F). A minimum of 2 technical replicates per cell line
(range 2–5) were performed for each of three SF3B1neutral and SF3B1loss cell lines. For
Figure 3E and S6B-D, loading control normalized AUCs were expressed as the fold change
relative to the diploid Cal51 cell line.
SF3B1 gene expression analysis from TCGA and CCLE datasets
Relative copy number and Affymetrix expression data for SF3B1 were downloaded from the
CCLE portal (http://www.broadinstitute.org/ccle/home). TCGA breast adenocarcinoma data
were downloaded from the cBioPortal (http://www.cbioportal.org/public-portal/index.do)
(Cerami et al., 2012; Gao et al., 2013). For both datasets, samples lacking either gene
expression or copy-number were removed. As described above, copy-loss was defined as
samples with log2 normalized relative copy number of < 0.35, copy gain was defined as 
0.3.
Spliceosome and DUBi drug viability assays
Cells were plated in 96 well plates at 10,000 cells per well. Relative viability was calculated as
the fold change in ATP luciferase luminescence units from Cell Titer Glo assays relative to
DMSO treated cells 48 hr after drug treatment (Figure 5—figure supplement 1F,
Figure 6H–I, Figure 8B,H and Figure 8—figure supplement 1D).
Immunoprecipitation
Immunoprecipitations were performed with pooled glycerol gradient fractions. The Fc region of
mouse anti-SF3B1 (Medical and Biological Laboratories, D221–3) was directionally cross-
linked to protein G Dynabeads (Life Technologies) using 20 mM dimethyl pimelimidate
(DMP). IgG isotype controls were cross-linked and processed identically. Proteins were
eluted with elution buffer (15% glycerol, 1% SDS, 50 mM tris-HCl, 150 mM NaCl pH 8.8) at
80C and subjected to western blot analysis.
U2 snRNA 2’ O-methyl oligonucleotide assays
2’ O-methyl oligonucleotides complementary to the branchpoint binding region of the U2
snRNA were synthesized by Integrative DNA Technologies with the following sequences:
(Branchpoint oligo) 5’mCmAmG mAmUmAmCmUmAmCmAmCmUmUmGmA,
(control oligo) 5’mAmCmUmGmUmAmCmUmAmAmCmUmGmAmCmUmG.
Experiments were performed as described in (Folco et al., 2012). Briefly, mini nuclear
extracts from SF3B1control-Cal51 and SF3B1Loss-Cal51 cells were generated using standard
protocols (Folco et al., 2012). U2 snRNA-targeting and control oligos were radiolabeled
with 32P-gamma ATP with T4 polynucleotide kinase. ATP was depleted from all extracts by
incubation at RT for 20 min. 300 ug of total protein from nuclear extracts were added to 25
uL reaction mixtures with or without 0.5 mM ATP, 3.2 mM MgCl2, and 20 mM creatine
phosphate (di-Tris salt). Reactions were incubated at 30C of 5 min before adding 34 ng of
either branchpoint-targeting or control oligo and subsequent incubation for another 5 min
at 30C. For reactions without ATP, water was used to raise the volume to 25 uL. Samples
were purified on microspin G-50 columns (GE) and loaded in a 1.2% low-melting agarose
gel.
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Nuclear speckle quantification by SC-35 immunofluorescence with
CellProfiler image analysis
Cells were plated on 35 mm glass bottom dishes with #1.5 cover glass (D35-14–1.5 N, In Vitro
Scientific). Cells were fixed and stained with anti-SC-35 antibody (S4045, Sigma-Aldrich) at
1:1000 dilution and detected with Alexafluor488 secondary antibody at 1:1000 (Life
Technologies). Nuclei were counterstained with Hoescht dye. Monochromatic images were
captured under identical conditions and pseudo-colored using Photoshop. A custom image
analysis pipeline was empirically adapted from a pre-existing pipeline designed for
detecting H2AX foci using CellProfiler (Kamentsky et al., 2011). Measurements of nuclear
speckles were generated from at least 15 random microscopic fields. A minimum of 100
nuclei identified by CellProfiler were used for quantitation per treatment.
Ki67 quantification from tumor xenografts
A custom image analysis pipeline was used to systematically quantify Ki67+ cells from tumor
xenografts using CellProfilier. A minimum of 3 tumors per group, totaling at least 2440
nuclei per tumor, was used to quantify the ratio of Ki67+ cells. At least five individual and
random microscopic images from each tumor were analyzed.
Luciferase splicing reporters
CMV-LUC2CP/intron/ARE (Luc-I in this manuscript, Addgene plasmid # 62858) and CMV-
LUC2CP/ARE (Luc-ORF in this manuscript, Addgene plasmid # 62857) were gifts from
Gideon Dreyfuss (Younis et al., 2010). Cells were transfected and hygromycin selected to
generate stable cell lines. Cells were then treated with b-AP15 and assayed for luciferase
luminescence 24 hr after treatment with the Luciferase Assay System kit (Promega). The fold
change in splicing was calculated as the ratio of Luc-I to Luc-ORF after normalizing to DMSO
treatment.
RNAseq analysis of splicing by juncBase and beta binomial
distribution
To identify common splicing alterations across cancer cell lines, we conducted the RNAseq
splicing analyses (Figure 6A and C and Figure 6—figure supplement 1D. only in the
patient derived cells lines. This was done to avoid overweighting the Cal 51 cell line from
which the isogenic system was generated. We then validated samples for intron retention in
both isogenic cells and those with naturally occurring copy number alterations in SF3B1
(Figure 6B).
JuncBASE was used to determine the spliced in/spliced out counts at each splice junction. In
the following section we will use intron retention as the example for the way our beta
binomial statistic works. The spliced in/spliced out counts at each junction were used to
create an estimate of the percent of transcripts with the intron retained (Percent Spliced In,
where the intron refers to the inclusion isoform; PSI) for each cell line. We estimated the
distribution of this statistic for each cell line in each condition (with and without SF3B1
suppression) using a beta binomial distribution in which spliced in and spliced out read
counts were the a and b terms, respectively. Because we only observe a finite number of
reads across the junction, the PSI obtained by simple division may not be accurate. We
capture the extent of this inaccuracy by calculating an estimate of the probability
distribution of the true PSI, given the read counts observed. The beta binomial distribution
is used in cases like this where one is attempting to obtain an estimate of the distribution of
a Bernoulli random variable (true PSI) from a set of observations of trials and successes. The
PSI (IR) for cell line i at intron j, is therefore estimated as:
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IRi;j ¼ Beta ai;j;bi;j
  
Where a ¼ nreads intron j retained in cell line i and b ¼ nreads intron j excised in cell line i
We then sought to quantify the probability distribution of the ratio of PSI’s (PSIR) in the
same cell line upon SF3B1 suppression. This ratio corresponds to the relative probability of
retaining intron j in cell line i, upon SF3B1 suppression. We base this calculation on the two
distributions:
IRi;j;no SF3B1 suppression ¼ Beta ai;j; no SF3B1 suppression;bi;j;no SF3B1 suppression
  
IRi;j; with SF3B1 suppression ¼ Beta ai;j;with SF3B1 suppression;bi;j;with SF3B1 suppression
  
We extend the following intuition concerning ratio distributions:
P Zð Þ ¼
Z1
0
Z1
0
X
Y
PðXÞ PðYÞ dX dY
where Z=X/Y and X and Y are independent and distributed between 0 and 1.
In this case, the relative risk of including an intron for cell line i and intron j is:
PSIRi;j ¼
IRi;j; with SF3B1 suppression
IRi;j;no SF3B1 suppression
P PSIRi;j
  
¼
R1
0
R1
0
X
Y
P xð Þ P yð Þ dx dy where x ¼ iri;j; with SF3B1 suppression and y ¼ iri;j; no SF3B1 suppression
This integral can be calculated exactly (Pham-Gia, 2000), by bootstrapping, or by
approximation with a discrete distribution. We used the latter approach due to issues with
numeric overflow in calculating the exact distribution and the computational inability to
perform fine enough sampling to obtain very small p-values (ie <10 9) using bootstrapping.
To compute the discrete approximation, we iterated through a discrete set of PSI ratios
spaced between 0.01 and 100. During each iteration, we calculated the joint distribution of
zi;j=x/y as above (where zi;j = PSIRi;jÞ: We sampled x (IRi;j; with SF3B1 suppression) at 1000 intervals
between 0 to 1 and calculated the set of y’s (IRi;j; no SF3B1 suppression) such that y=x/z. We then
calculated the joint probability of x and y for all x,y combinations and summed these values
to calculate the probability of observing a given relative risk zi;j. The discrete probability
distribution of zi;j was then normalized to 1 to achieve the final probability distribution on
the PSI ratio for intron j in cell line i upon SF3B1 suppression.
A posterior estimate of the probability distribution of the PSI ratio in SF3B1loss cell lines
PSIRSF3B1lossð Þwas then obtained by a point-wise multiplication of the distributions PSIRi;j
PSIRSF3B1loss xð Þ /
Y
PSIRi;j
for all cell lines with the genotype SF3B1loss. The same procedure was used to calculate the
posterior estimate of the PSI ratio for intron retention in SF3B1neutral cell lines PSIRSF3B1neutral.
Finally, we calculated the p-values for the difference between the distributions PSIRSF3B1loss
and PSIRSF3B1neutral. This p-value represents the area of overlap of the two distributions and
can be obtained by integrating proportion of the convolution of the PSIRSF3B1loss and
PSIRSF3B1neutral that is greater than 0.
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PðnhÞ ¼
Z¥
0
PSIRSF3B1loss* PSIRSF3B1neutral½ 
Where P nhð Þ is the probability of the null hypothesis that the true values of PSIRSF3B1loss and
PSIRSF3B1neutral are equal. Multiple hypothesis correction was performed using the Benjamini-
Hochberg method (Benjamini and Hochberg, 1995).
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